Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Truscreen GroupASX:TRU EV-to-EBITDA is -5.67 as of Aug. 13, 2026. The stock has 4 warning signs investors should review. Among 514 Medical Devices & Instruments companies, Truscreen Group ranks worse than 194552.33% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Truscreen Group's enterprise value is A$11.55 Mil.
Truscreen Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$-2.04 Mil. Therefore, Truscreen Group's EV-to-EBITDA for today is -5.67.
The historical rank and industry rank for Truscreen Group's EV-to-EBITDA or its related term are showing as below:
ASX:TRU'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -42.91 Med: -5.18 Max: -0.95
Current: -6.23
During the past 12 years, the highest EV-to-EBITDA of Truscreen Group was -0.95. The lowest was -42.91. And the median was -5.18.
ASX:TRU's EV-to-EBITDA is ranked worse than 100% of 514
companies
in the Medical Devices & Instruments industry
Industry Median: 14.825
vs ASX:TRU: -6.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Truscreen Group (ASX:TRU) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Truscreen Group's PE Ratio (TTM) for today is calculated as:
Truscreen Group's share price for today is A$0.012.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Truscreen Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$-0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Truscreen Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Truscreen Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Truscreen Group EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Truscreen Group's EV-to-EBITDA falls into.
Truscreen Group's current Enterprise Value is A$11.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Truscreen Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$-2.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Truscreen Group (ASX:TRU) has a EV-to-EBITDA of -5.67 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Truscreen Group. According to the industry distribution chart, Truscreen Group ranks #999999 out of 514 companies in the Medical Devices & Instruments industry.
Is Truscreen Group's EV-to-EBITDA too high?
Truscreen Group's current EV-to-EBITDA is -5.67. Based on the distribution chart, Truscreen Group ranks #999999 out of 514 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Truscreen Group's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Truscreen Group ranks #999999 out of 514 companies for EV-to-EBITDA. This places Truscreen Group in the lower half of its industry. The industry median EV-to-EBITDA is 14.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.83, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Truscreen Group. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Truscreen Group's current EV-to-EBITDA is -5.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 20% above its estimated fair value. The current EV-to-EBITDA is -5.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current EV-to-EBITDA is -5.67 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRU has been successfully added to your 
